This protocol applies to patients with neurological symptoms of Wilson's disease in whom the initial management strategy — reducing chelator doses, slowing dose escalation, and discontinuing dopamine receptor antagonists — did not achieve the expected therapeutic goals.
The first-line approach aimed at resolving paradoxical neurological worsening and achieving progressive improvement in neurological symptoms with a decrease or normalisation of the UWDRS score. Failure to reach these endpoints is the trigger for escalation to this next protocol step.
This protocol involves switching the Wilson's disease treatment regimen. A change in treatment class is central to the approach, with second-line options available. The complete switching algorithm — which agents, in what order, and under what conditions — is available in the full protocol.
The target is progressive improvement of neurological symptoms, with decrease or normalisation of the UWDRS score as the primary measurable endpoint of treatment response.
DOI: 10.1016/j.jhep.2024.11.007